Wednesday, Dec 22, 2004
South San Francisco, Calif. -- December 22, 2004 --Genentech, Inc. (NYSE:DNA) today announced that the company's board elected David Ebersman to senior vice president, Finance and Patrick Y. Yang, Ph.D., to senior vice president, Product Operations. Timothy L. Moore was appointed vice president, South San Francisco Manufacturing.
Genentech also announced three senior appointments in the company's Commercial Operations organization: Kent Lieginger, Pharm.D., vice president, Managed Care and Customer Operations; Kevin McRaith, vice president, Hematology Sales and Marketing; and John Orwin, vice president, Human EGF-Receptor (HER) Family* Product Sales and Marketing.
Genentech's board of directors elected David Ebersman, 35, as senior vice president, Finance and Patrick Y. Yang, 56, as senior vice president, Product Operations. Both report to chairman and chief executive officer Arthur D. Levinson, Ph.D.
Ebersman, a member of Genentech's Executive Committee and formerly senior vice president, Product Operations, will assume Louis J. Lavigne Jr.'s role as chief financial officer upon Lavigne's retirement in March 2005. Ebersman will be responsible for Genentech's Finance, Corporate Relations, Investor Relations and Corporate Information Technology groups. Lavigne's retirement was announced in November, and Ebersman and Lavigne will work together over the next several months to ensure a smooth transition of roles.
Yang, formerly Genentech's vice president of South San Francisco Manufacturing and Engineering, was promoted to senior vice president, Product Operations. In his new role, he will be responsible for Genentech's Manufacturing, Engineering, Process Development and Supply Chain Management organizations. Prior to joining Genentech in 2003, Yang was a vice president in Merck's Manufacturing Division.
The company also announced the appointment of Timothy L. Moore, 43, as vice president of South San Francisco Manufacturing. Moore, currently vice president of Corporate Engineering, will report to Yang and will assume responsibility for both South San Francisco Manufacturing and Corporate Engineering groups until the appointment of a vice president of Corporate Engineering. Moore joined Genentech in July 2004 from ZLB Behring (formerly Aventis Behring), where he managed aseptic/biological manufacturing operations.
The appointments of Ebersman and Yang are effective January 5, 2005. Moore's appointment is effective immediately.
Kent Lieginger, Pharm.D.
Managed Care and Customer Operations
Kent Lieginger, 53, joins Genentech as vice president, Managed Care and Customer Operations, reporting to Myrtle Potter, president, Commercial Operations. In this newly created position, Lieginger will be responsible for strategically aligning two distinct operating groups, Managed Care and Commercial Operations Support Service (COSS). Lieginger will also serve as a member of the Commercial Leadership Committee.
"Kent brings to Genentech more than 20 years of industry experience, including leadership roles in sales, marketing, business development and managed care," said Potter. "The Managed Care and Commercial Operations Support Services groups are of growing importance within the organization. Kent's strong industry expertise and solid experience as a strategic leader will help support our growth."
Lieginger joins Genentech from GlaxoSmithKline, where he was vice president, National Insurer and Employer Segment, Managed Markets division.
Lieginger served for four years as assistant clinical professor of Medicine at the University of California, Davis, School of Medicine. He received a Pharm.D. degree at the University of the Pacific in Stockton, and completed his residency in Clinical Pharmacy at the University of California, San Francisco.
Hematology Sales and Marketing
Kevin McRaith, 40, joins Genentech as vice president, Hematology Sales and Marketing, reporting to Ian Clark, senior vice president and general manager, BioOncology. McRaith will be responsible for leadership and development of the Hematology product portfolio, including sales and marketing activities, and the business's life cycle plans.
"Kevin has extensive experience in a wide range of therapeutic areas and has successfully led products and teams through every aspect of their life cycles," said Clark. "He is well suited to lead the Hematology team."
McRaith joins Genentech from Abbott Laboratories, where he most recently served as the general manager for the company's top-selling antibiotic. Prior, he was director of Marketing for Abbott's Neuroscience franchise. He has held various sales and marketing leadership roles at Abbott as well as Baxter Healthcare Corporation.
McRaith holds a Bachelor of Science degree in Liberal Arts from the University of Iowa.
HER Family Product Sales and Marketing
John Orwin, 40, joins Genentech as vice president, HER Family Product Sales and Marketing, also reporting to Clark. Orwin will be responsible for leadership and development of the HER family product portfolio, including sales and marketing activities, and the business's life cycle plans.
"John has more than 15 years of experience in the pharmaceutical industry that includes senior leadership roles in business development, sales and marketing," said Clark. "His combination of leadership and strong oncology experience will be a great fit for the HER family."
Orwin joins Genentech from Johnson & Johnson's Ortho Biotech division, where he most recently was franchise vice president, Oncology, of the Tibotec Therapeutics group. Orwin has held senior marketing and sales positions with Schering-Plough, Rhone-Poulenc Rorer, Sangstat Medical Corporation and Alza Pharmaceuticals.
Orwin holds a Master of Business Administration from the Stern School of Business, New York University and a Bachelor of Arts degree in Economics from Rutgers University.
Genentech is a leading biotechnology company that discovers, develops, manufactures, and commercializes biotherapeutics for significant unmet medical needs. A considerable number of the currently approved biotechnology products originated from, or are based on, Genentech science. Genentech manufactures and commercializes multiple biotechnology products directly in the United States, and receives royalties or other income from companies that are licensed to market its products outside of the United States. The company has headquarters in South San Francisco, Calif., and is traded on the New York Stock Exchange under the symbol DNA. For additional information about the company, please visit http://www.gene.com.
* The HER family includes the oncology products Herceptin® and Tarceva.